Chardan Capital Maintains Buy on Zura Bio, Maintains $10 Price Target
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Daniil Gataulin maintains Zura Bio (NASDAQ:ZURA) with a Buy and maintains $10 price target.
Chardan Capital analyst Daniil Gataulin maintains Zura Bio (NASDAQ:ZURA) with a Buy and maintains $10 price target.